<DOC>
	<DOCNO>NCT02390947</DOCNO>
	<brief_summary>Famitinib tyrosin-inhibitor agent target c-Kit , VEGFR2 , PDGFR , VEGFR3 , Flt1 Flt3 , whose anti-tumor anti-angiogenesis effect validate preclinical test . In PhaseⅡb study , significantly improve Progression Free Survival ( PFS ) find patient advanced colorectal cancer treat Famitinib compare placebo . On hand , toxicity Famitinib manageable PhaseⅠand Ⅱb study . The purpose study determine whether Famitinib improve Overall Survival ( OS ) compare placebo total 540 patient advanced colorectal cancer fail previously receive least two line standard chemotherapy .</brief_summary>
	<brief_title>Safety Efficacy Study Famitinib Patients With Advanced Colorectal Adenocarcinoma（FACT）</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>1 . Male female patient age 18 75 ( include 18 75 ) time Informed Consent 2 . Pathologically confirm advanced colorectal adenocarcinoma ( histological type exclude ) 3 . Treatment failure previously receive standard therapy ( least two line ) , must include 5Fu , irinotecan oxaliplatin Definition `` treatment failure '' : A.Disease progression experimental drug treatment within 3 month last treatment , definite image clinical evidence ; B.For patient abandon chemotherapy intolerance advent event , hematologic toxicity require reach ≥Grade IV ( platelet decrease ≥ Grade III ) , nonhematologic toxicity require reach ≥Grade III , accord NCI CTCAE 4.0 . Furthermore , original treatment tolerate repeated patient , judge investigator . Note : A.When adjuvant therapy include oxaliplatin previously use , least 9 course FOLFOX ( 2 week regimen ) , 6 course CapeOX ( 3 week regimen ) , 750mg/m^2 cumulative consumption oxaliplatin , require . Adjuvant therapy regard firstline treatment disease progress within 6 month treatment B.Monoclonal antibody drug ( bevacizumab , cetuximab , panitumumab , aflibercept , etc . ) allow combine prior chemotherapy . 4 . At least one measurable target lesion accord RECIST 1.1 ( The diameter tumor lymph node lesion ≥ 10 mm 15mm , respectively , scan layer ≤ 5 mm without local treatment ) 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status:01 . 6 . Life expectancy ≥ 3 month 7 . Adequate function major organ , mean follow criterion meet within 14 day randomization : A.Routine blood test : 1 . Hemoglobin &gt; 90g/L ( receive blood transfusion drug incraese RBC , Hb , WBC PLT 14 day screen ) 2 . Neutrophils &gt; 1.5×10^9/L 3 . Platelets &gt; 100×10^9/L B . Blood biochemistry : 4 . Total bilirubin &lt; 1.25×the upper limit normal ( ULN ) 5 . Serum transaminase ≤ 2×ULN ( ≤ 5×ULN , If exist liver metastasis ) 6 . Creatinine clearance rate ≥ 60ml/min ( CockcroftGault Formula ) C.Doppler echocardiography assessment : Left ventricular ejection fraction ( LVEF ) ≥ 50 % 8 . Having recovered impairment therapy take research drug ( 6 week last treatment Nitroso MMC , 4 week last treatment cytotoxic drug , target drug , radiotherapy operation , completely heal wound , 2 week last treatment Chinese traditional patent medicine ) 9 . Signed date informed consent 10 . Good compliance patient agreement family member cooperate followup survival . 1 . Second malignancy , except cure skin basal cell carcinoma carcinoma insitu uterine cervix , screen 2 . Previously receive therapy tyrosine kinase inhibitor agent target VEGFR , e.g . famitinib , sorafenib , sunitinib , regorafenib 3 . Having join clinical trial within 4 week 4 . Factors influence usage oral administration ( e.g . unable swallow , chronic diarrhea intestinal obstruction , etc . ) 5 . Having haemorrhage history , ≥ Grade Ⅲ ( NCI CTCAE 4.0 ) haemorrhage occur within 4 week screen 6 . Known central nervous system ( CNS ) metastasis CNS metastasis history screening . CT MRI scan receive 28 day randomization CNS metastases clinically suspect 7 . Uncontrolled hypertension single medical therapy ( systolic blood pressure &gt; 140 mmHg , diastolic blood pressure &gt; 90 mmHg ) , History unstable angina pectoris newly diagnose unstable angina pectoris within 3 month screen , myocardial infarction event within 6 month screen , Arrhythmias ( QTcF : ≥450ms male , ≥ 470ms female ) need longterm treatment drug , ≥ class II cardiac insufficiency New York Heart Association ( NYHA ) classification 8. urinary protein ≥ ++ 24hour urinary protein ≥ 1.0 g 9 . Chronic untreated wound fracture 10 . Tumor invasion around major vessel show imaging , high risk major vascular invasion lead massive hemorrhage judge investigator 11 . Abnormal international normalize ratio ( INR ) patient coagulation dysfunction hemorrhagic tendency 14 day randomization . Application anticoagulant vitamin K antagonist warfarin , heparin analogue . However , low dos warfarin ( 1mg orally , daily ) aspirin ( 80mg 100mg daily ) use prevention premise INR ≤ 1.5 12 . Artery/venous thromboembolic event occur within 1 year screening , cerebral vascular accident ( include transient ischemic attack ) , deep vein thrombosis ( except recover venous thrombosis judge investigator , cause venous catheter previous chemotherapy ) pulmonary embolism , etc . 13 . All female patient surgically sterilize postmenopausal refuse take reliable method birth control study within 6 month last dose test article . All female patient breastfeed period childbearing period positive urine serum pregnancy test result randomization . All male subject surgically sterilize refuse take reliable method birth control study within 6 month last dose test article . 14 . Preexisted thyroid dysfunction , thyroid function control within normal range even use medical therapy 15 . History psychiatric drug abuse addiction , dysphrenia 16 . Symptomatic pleural effusion , hydropericardium ascites need clinical intervention stable le 4 week . 17 . History Immunodeficiency , acquire congenital immunodeficiency , history organ transplantation 18 . Known active HBV HCV infection companion hepatic dysfunction 19 . Concomitant disease judge investigator may bring serious harm safety patient completion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Colorectal Cancer</keyword>
	<keyword>Famitinib</keyword>
</DOC>